Immune Repertoire is the collection of B and T cells with functional diversity in the body that reflects the immune selectivity. Immune Repertoire Sequencing means to sequence the complimentary determining region of both B-cell receptor and T-cell receptor. Immune receptor repertoire profiling portrays as the antigen-specific information within lymphocytes and has become increasingly significant to understand body’s autoimmunity and healthy immunity. This also propose novel ways to tackle cancer and development of personalized medicine by understanding the genetic makeup of a person. Since the last two decades, the technical advancements in the high throughput sequencing techniques along with the development in the bioinformatics and statistical tools have made the immune repertoire sequencing to be analyzed at single sequence level. This technology has potential to explore for the novel infectious agents and also offers new approaches for vaccine or antibody development.
Clinical immune repertoire sequencing has a large awaiting market because multiplexing all possible V (D) J combinations into a single assay significantly decreases material and labor costs. Nowadays, next generation sequencing techniques overcomes the traditional strategies for studying the immune repertoire. The most commonly used platforms for immune repertoire sequencing is Illumina and Roche 454. However, the clinical use applications of immune repertoire sequence studies is massive, still more work remains to be completed to integrate the experiential dynamic changes with clinical features and outcomes.
The growth in the high throughput sequencing techniques, new statistical and bioinformatics tools drives the Immune Repertoire Sequencing market. Increasing innovation and technology, extensive research, government funding, various applications of the technique is going to fuel the market. However, expensive machinery, algorithmic challenges, non-availability in every region, professional expertise are some of the challenges that restraints the market of DNA sequencing from growing. Real time monitoring, high accuracy and sensitivity is the demand in this industry.
Adaptive Bio, one of the key player in Immune Repertoire Sequencing estimated that the research market for immune profiling in blood-based cancers could reach $390 million by 2018, while the diagnostic market could be $850 million. Recently in 2016, Immuno-oncology firm Argos Therapeutics has announced a research agreement with Seattle-based Adaptive Biotechnologies to study patient response to investigational immunotherapies. ArcherDX, one of the leader in NGS-based fusion assays, released the Archer Immunoverse immune repertoire sequencing assays. Recently in 2016, Seattle-based Juno Therapeutics has acquired AbVitro, an immune repertoire analysis company for $125 million. These trends directly shows a future probability of growth in this sector.
Based on geography, DNA Sequencing market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and the Middle East & Africa. North America dominates the market followed by Europe in the use of high-throughput sequencers owing to the availability of skilled professionals and developing innovations in the sequencing technology. Asia-Pacific is expected to grow in the future because of the increasing government funds in the research sector, growing focus on cancer research by CROs and biopharmaceutical companies.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/14911
Some of the key market players in the DNA sequencing market are Siemens AG, Pacific Biosciences, Eppendorf, Perkin Elmer, Agilent Technologies Inc., Illumina, Genia Corporation, Oxford Nanopore technologies, Roche Holdings AG, ThermoFisher Scientific and many others .
Some of the key players in the Immune Repertoire Sequencing market includes ArcherDX, Inc., Junom Therapeutics, Roche Holding AG, Illumina Inc., ThermoFisher Scietific, Pacific Biosciences, CD Genomics, Atreca, Inc., Adaptive Biotechnologies and many more.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/14911